{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:13:13Z","timestamp":1773281593452,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1208\/s12249-017-0712-6","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T11:54:22Z","timestamp":1484740462000},"page":"2291-2302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma"],"prefix":"10.1208","volume":"18","author":[{"given":"A.","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Opere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"key":"712_CR1","unstructured":"National Eye Health Education Program (NEHEP). https:\/\/nei.nih.gov\/nehep\/gam\/ . Accessed 23 Sep 2016."},{"key":"712_CR2","unstructured":"Bulletin of the World Health Organization (WHO). Glaucoma is second leading cause of blindness globally. 2004. http:\/\/www.who.int\/bulletin\/volumes\/82\/11\/feature1104\/en\/ . Accessed 23 Sep 2016."},{"key":"712_CR3","unstructured":"Glaucoma facts and stats. http:\/\/www.glaucoma.org\/glaucoma\/glaucoma-facts-and-stats.php . Accessed 23 Sep 2016."},{"key":"712_CR4","first-page":"714","volume":"21","author":"J Alvarado","year":"1981","unstructured":"Alvarado J, Murphy C, Polansky J, Juster R. Age-related changes in trabecular meshwork cellularity. Invest Ophthalmol Vis Sci. 1981;21:714\u201327.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"712_CR5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2012.09.008","volume":"13","author":"V Chrysostomou","year":"2013","unstructured":"Chrysostomou V, Rezania F, Trounce I, Crowston J. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol. 2013;13:12\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"712_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.E003533","volume":"51","author":"SJ Fliesler","year":"2010","unstructured":"Fliesler SJ. Lipids and lipid metabolism in the eye. J Lipid Res. 2010;51:1\u20133.","journal-title":"J Lipid Res"},{"key":"712_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2005.11.001","volume":"612","author":"A Izzotti","year":"2006","unstructured":"Izzotti A, Bagnis A, Sacc\u00e0 SC. The role of oxidative stress in glaucoma. Mutat Res. 2006;612:105\u201314.","journal-title":"Mutat Res"},{"key":"712_CR8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1167\/iovs.08-2717","volume":"50","author":"G Tezel","year":"2009","unstructured":"Tezel G. The role of glia, mitochondria, and the immune system in glaucoma. Invest Ophthalmol Vis Sci. 2009;50:1001\u201312.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"712_CR9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.drudis.2010.02.007","volume":"15","author":"A Dahlmann-Noor","year":"2010","unstructured":"Dahlmann-Noor A, Vijay S, Limb GA, Khaw P. Strategies for optic nerve, rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today. 2010;15:287\u201399.","journal-title":"Drug Discov Today"},{"key":"712_CR10","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.4103\/0301-4738.73700","volume":"59","author":"SK Vasudevan","year":"2011","unstructured":"Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol. 2011;59:S102\u201313.","journal-title":"Indian J Ophthalmol"},{"key":"712_CR11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/eop.10.55","volume":"5","author":"B Chua","year":"2010","unstructured":"Chua B, Goldberg I. Neuroprotective agents in glaucoma therapy: recent developments and future directions. Expert Rev Ophthalmol. 2010;5:627\u201336.","journal-title":"Expert Rev Ophthalmol"},{"key":"712_CR12","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","volume":"108","author":"PR Lichter","year":"2001","unstructured":"Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943\u201353.","journal-title":"Ophthalmology"},{"key":"712_CR13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"712_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0953-816X.2003.03107.x","volume":"19","author":"J Ji","year":"2004","unstructured":"Ji J, Elyaman W, Yip HK, Lee VW, Yick LW, Hugon J, et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur J Neurosci. 2004;19:265\u201372.","journal-title":"Eur J Neurosci"},{"key":"712_CR15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1073\/pnas.91.5.1632","volume":"91","author":"S Mansour-Robaey","year":"1994","unstructured":"Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci U S A. 1994;91:1632\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"712_CR16","first-page":"489","volume":"37","author":"P Peinado-Ram\u00f3n","year":"1996","unstructured":"Peinado-Ram\u00f3n P, Salvador M, Villegas-P\u00e9rez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996;37:489\u2013500.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"712_CR17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0079-6123(08)01124-2","volume":"173","author":"NN Osborne","year":"2008","unstructured":"Osborne NN. Pathogenesis of ganglion \u201ccell death\u201d in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res. 2008;173:339\u201352.","journal-title":"Prog Brain Res"},{"key":"712_CR18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuint.2012.01.015","volume":"60","author":"NN Osborne","year":"2012","unstructured":"Osborne NN, Ji D, Majid ASA, Del Soldata P, Sparatore A. Glutamate oxidative injury to RGC-5 cells in culture is necrostatin sensitive and blunted by a hydrogen sulfide (H2S)-releasing derivative of aspirin (ACS14). Neurochem Int. 2012;60:365\u201378.","journal-title":"Neurochem Int"},{"key":"712_CR19","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.neuint.2013.04.001","volume":"62","author":"J Jia","year":"2013","unstructured":"Jia J, Xiao Y, Wang W, Qing L, Xu Y, Song H, et al. Differential mechanisms underlying neuroprotection of hydrogen sulfide donors against oxidative stress. Neurochem Int. 2013;62:1072\u20138.","journal-title":"Neurochem Int"},{"key":"712_CR20","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1161\/STROKEAHA.110.589697","volume":"41","author":"J Li","year":"2010","unstructured":"Li J, Benashski SE, Venna VR, McCullough LD. Effects of metformin in experimental stroke. Stroke. 2010;41:2645\u201352.","journal-title":"Stroke"},{"key":"712_CR21","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1093\/emboj\/20.21.6008","volume":"20","author":"W Zhao","year":"2001","unstructured":"Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001;20:6008\u201316.","journal-title":"EMBO J"},{"key":"712_CR22","first-page":"856","volume":"2009","author":"KR Olson","year":"1787","unstructured":"Olson KR. Is hydrogen sulfide a circulating \u201cgasotransmitter\u201d in vertebrate blood? Biochim Biophys Acta. 1787;2009:856\u201363.","journal-title":"Biochim Biophys Acta"},{"key":"712_CR23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/ars.2006.8.661","volume":"8","author":"Y Kimura","year":"2006","unstructured":"Kimura Y, Dargusch R, Schubert D, Kimura H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signal. 2006;8:661\u201370.","journal-title":"Antioxid Redox Signal"},{"key":"712_CR24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1096\/fj.04-1815fje","volume":"18","author":"Y Kimura","year":"2004","unstructured":"Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J. 2004;18:1165\u20137.","journal-title":"FASEB J"},{"key":"712_CR25","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1089\/ars.2010.3544","volume":"14","author":"P Weisova","year":"2011","unstructured":"Weisova P, Davila D, Tuffy LP, Ward MW, Concannon CG, Prehn JH. Role of 5\u2032-adenosine monophosphate-activated protein kinase in cell survival and death responses in neurons. Antioxid Redox Signal. 2011;14:1863\u201376.","journal-title":"Antioxid Redox Signal"},{"key":"712_CR26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.bmcl.2009.02.007","volume":"19","author":"E Perrino","year":"2009","unstructured":"Perrino E, Uliva C, Lanzi C, Soldato PD, Masini E, Sparatore A. New prostaglandin derivative for glaucoma treatment. Bioorg Med Chem Lett. 2009;19:1639\u201342.","journal-title":"Bioorg Med Chem Lett"},{"key":"712_CR27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/jop.2015.0144","volume":"32","author":"A Salvi","year":"2016","unstructured":"Salvi A, Bankhele P, Jamil J, Chitnis MK, Njie-Mbye YF, Ohia SE, et al. Effect of hydrogen sulfide donors on intraocular pressure in rabbits. J Ocul Pharmacol Ther. 2016;32:371\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"712_CR28","first-page":"3563","volume":"54","author":"YF Njie-Mbye","year":"2013","unstructured":"Njie-Mbye YF, Robinson J, Okpobiri A, Chitnis M, Opere C, Ohia S. Effect of NaHS, a fast-releasing hydrogen sulfide donor on aqueous humor outflow in porcine trabecular meshwork. Invest Ophthalmol Vis Sci. 2013;54:3563.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"712_CR29","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1039\/C5MD00170F","volume":"6","author":"BE Alexander","year":"2015","unstructured":"Alexander BE, Coles SJ, Fox BC, Khan TF, Maliszewski J, Perry A, et al. Investigating the generation of hydrogen sulfide from the phosphonamidodithioate slow-release donor GYY4137. Med Chem Commun. 2015;6:1649\u201355.","journal-title":"Med Chem Commun"},{"key":"712_CR30","first-page":"159680","volume":"2012","author":"M Bhatia","year":"2012","unstructured":"Bhatia M. Role of hydrogen sulfide in the pathology of inflammation. Scientifica (Cairo). 2012;2012:159680.","journal-title":"Scientifica (Cairo)"},{"key":"712_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/2212703801666140311005131","volume":"1","author":"N Muniraj","year":"2014","unstructured":"Muniraj N, Ang AD, Badiei A, Rivers-Auty J, Bhatia M. Hydrogen sulfide: a new tool to design and develop drugs. Clin Antiinflamm Anti-Allergy Drugs. 2014;1:57\u201366.","journal-title":"Clin Antiinflamm Anti-Allergy Drugs"},{"key":"712_CR32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1208\/s12249-014-0117-8","volume":"15","author":"H Ali","year":"2014","unstructured":"Ali H, Opere C, Singh S. In vitro-controlled release delivery system for hydrogen sulfide donor. AAPS PharmSciTech. 2014;15:910\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"712_CR33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4236\/abc.2012.24044","volume":"2","author":"AD Ang","year":"2012","unstructured":"Ang AD, Konigstorfer A, Giles GI, Bhatia M. Measuring free tissue sulfide. Adv Biol Chem. 2012;2:360\u20135.","journal-title":"Adv Biol Chem"},{"key":"712_CR34","unstructured":"Validation of compendial procedures, USP 39, pp. 1640-6, http:\/\/www.uspnf.com\/uspnf\/pdf\/download?usp=39&nf=34&s=2&q=usp39nf34s2_c1225.pdf&officialOn=December%201,%202016&target=oldwindow&time=1481557962512 . Accessed 12 Dec 2016."},{"key":"712_CR35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jps.2600710726","volume":"71","author":"WL Hayton","year":"1982","unstructured":"Hayton WL, Chen T. Correction of perfusate concentration for sample removal. J Pharm Sci. 1982;71:454\u20138.","journal-title":"J Pharm Sci"},{"key":"712_CR36","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1016\/j.tetlet.2007.06.090","volume":"48","author":"K Bravo-Altamirano","year":"2007","unstructured":"Bravo-Altamirano K, Montchamp JL. A novel approach to phosphonic acids from hypophosphorous acid. Tetrahedron Lett. 2007;48:5755\u20139.","journal-title":"Tetrahedron Lett"},{"key":"712_CR37","unstructured":"GYY 4137 Product Insert, Cayman chemicals specification. https:\/\/www.caymanchem.com\/pdfs\/13345.pdf . Accessed 23 Sep 2016."},{"key":"712_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3940(00)01546-9","volume":"294","author":"M Takeda","year":"2000","unstructured":"Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S, et al. Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett. 2000;294:97\u2013100.","journal-title":"Neurosci Lett"},{"key":"712_CR39","first-page":"1848","volume":"19","author":"The Editors of Molecular Vision","year":"2013","unstructured":"The Editors of Molecular Vision. On authentication of cell lines. Mol Vis. 2013;19:1848\u201351.","journal-title":"Mol Vis"},{"key":"712_CR40","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/0016-7037(89)90053-7","volume":"53","author":"JJ Carroll","year":"1989","unstructured":"Carroll JJ, Mather AE. The solubility of hydrogen sulphide in water from 0 to 90\u00b0C and pressures to 1 MPa. Geochim Cosmochim Acta. 1989;53:1163\u201370.","journal-title":"Geochim Cosmochim Acta"},{"key":"712_CR41","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.freeradbiomed.2009.09.018","volume":"47","author":"MN Hughes","year":"2009","unstructured":"Hughes MN, Centelles MN, Moore KP. Making and working with hydrogen sulfide: the chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review. Free Radic Biol Med. 2009;47:1346\u201353.","journal-title":"Free Radic Biol Med"},{"key":"712_CR42","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1161\/CIRCULATIONAHA.107.753467","volume":"117","author":"L Li","year":"2008","unstructured":"Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, et al. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation. 2008;117:2351\u201360.","journal-title":"Circulation"},{"key":"712_CR43","volume":"6","author":"ZW Lee","year":"2011","unstructured":"Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, et al. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One. 2011;6, e21077.","journal-title":"PLoS One"},{"key":"712_CR44","doi-asserted-by":"publisher","first-page":"691070","DOI":"10.1155\/2015\/691070","volume":"2015","author":"G Meng","year":"2015","unstructured":"Meng G, Zhu J, Xiao Y, Huang Z, Zhang Y, Tang X, et al. Hydrogen sulfide donor GYY4137 protects against myocardial fibrosis. Oxidative Med Cell Longev. 2015;2015:691070. doi: 10.1155\/2015\/691070 .","journal-title":"Oxidative Med Cell Longev"},{"key":"712_CR45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-3-319-18144-8_17","volume":"230","author":"M Whiteman","year":"2015","unstructured":"Whiteman M, Zhou, Perry A, Bucci M, Papapetropoulos A, Cirino G, et al. Phospinodithioate and phosphoramidodithioate hydrogen sulfide donors. Handb Exp Pharmacol. 2015;230:337\u201363.","journal-title":"Handb Exp Pharmacol"},{"key":"712_CR46","volume":"9","author":"M Thomsen","year":"2014","unstructured":"Thomsen M, Hernandez-Garcia A, Mathiesen J, Poulsen M, S\u00f8rensen DN, Tarnow L, et al. Model study of the pressure build-up during subcutaneous injection. PLoS One. 2014;9, e104054.","journal-title":"PLoS One"},{"key":"712_CR47","first-page":"30","volume":"2","author":"KS Rathore","year":"2010","unstructured":"Rathore KS. In\u00adsitu gelling ophthalmic drug delivery system: an overview. Int J Pharm Sci. 2010;2:30\u20134.","journal-title":"Int J Pharm Sci"},{"key":"712_CR48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","volume":"12","author":"F Cilurzo","year":"2011","unstructured":"Cilurzo F, Selmin F, Minghetti P, Adami M, Bertoni E, Lauria S, et al. Injectability evaluation: an open issue. AAPS PharmSciTech. 2011;12:604\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"712_CR49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/la9023426","volume":"26","author":"MA Miller","year":"2010","unstructured":"Miller MA, Engstrom JD, Ludher BS, Johnston KP. Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles. Langmuir. 2010;26:1067\u201374.","journal-title":"Langmuir"},{"issue":"3","key":"712_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1582-4934.2009.00645.x","volume":"13","author":"M Whiteman","year":"2009","unstructured":"Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med. 2009;13(3):488\u2013507. doi: 10.1111\/j.1582-4934.2009.00645.x .","journal-title":"J Cell Mol Med"},{"key":"712_CR51","unstructured":"Aldrich DS, Bach CM, Brown W, Wiley Chambers W, Fleitman, J, Hunt D, et al. Ophthalmic preparations. http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/meetings\/workshops\/ophthalmicpreparations.pdf . Accessed 23 Sep 2016."},{"key":"712_CR52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-3-319-25498-2","volume-title":"Pharmacology of ocular therapeutics","author":"T Velapandian","year":"2016","unstructured":"Velapandian T. Pharmacology of ocular therapeutics. New York: Springer Cham Heidelberg; 2016. p. 395\u20136."},{"key":"712_CR53","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/ICO.0000000000000257","volume":"33","author":"M Schargus","year":"2014","unstructured":"Schargus M, Wolf F, Tony HP, Meyer-Ter-Vehn T, Geerling G. Correlation between tear film osmolarity, dry eye disease, and rheumatoid arthritis. Cornea. 2014;33:1257\u201361.","journal-title":"Cornea"},{"key":"712_CR54","first-page":"140","volume":"5","author":"CC Mitsch","year":"1971","unstructured":"Mitsch CC, Freedman LD, Moreland CG. Substituent and solvent effects on the 31P NMR chemical shifts of substituted diethyl phenylphosphonates. J Magn Reson. 1971;5:140\u20134.","journal-title":"J Magn Reson"},{"key":"712_CR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0039-9140(94)80110-X","volume":"41","author":"I Butler","year":"1994","unstructured":"Butler I, Schoonen M, Rickard D. Removal of dissolved oxygen from water: a comparison of four common techniques. Talanta. 1994;41:211\u20135.","journal-title":"Talanta"},{"key":"712_CR56","first-page":"217","volume":"67","author":"S Dash","year":"2010","unstructured":"Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217\u201323.","journal-title":"Acta Pol Pharm"},{"key":"712_CR57","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/jps.2600570206","volume":"57","author":"JB Schwartz","year":"1968","unstructured":"Schwartz JB, Simonelli AP, Higuchi WI. Drug release from wax matrices. I. Analysis of data with first-order kinetics and with the diffusion-controlled model. J Pharm Sci. 1968;57:274\u20137.","journal-title":"J Pharm Sci"},{"key":"712_CR58","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/jps.24673","volume":"104","author":"L Solorio","year":"2015","unstructured":"Solorio L, Exner AA. Effect of the subcutaneous environment on phase-sensitive in situ-forming implant drug release, degradation, and microstructure. J Pharm Sci. 2015;104:4322\u20138.","journal-title":"J Pharm Sci"},{"key":"712_CR59","unstructured":"Connaughton V. Glutamate and glutamate receptors in the vertebrate retina. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11526\/pdf\/Bookshelf_NBK11526.pdf . Accessed 23 Sep 2016."},{"key":"712_CR60","first-page":"1618","volume":"37","author":"CK Vorwerk","year":"1996","unstructured":"Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618\u201324.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"712_CR61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-3209-8_19","volume":"801","author":"C Sippl","year":"2014","unstructured":"Sippl C, Tamm ER. What is the nature of the RGC-5 cell line? Adv Exp Med Biol. 2014;801:145\u201354.","journal-title":"Adv Exp Med Biol"},{"key":"712_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fncel.2015.00091","volume":"9","author":"AA Kritis","year":"2015","unstructured":"Kritis AA, Stamoula EG, Paniskaki KA, Vavilis TD. Researching glutamate - induced cytotoxicity in different cell lines: a comparative\/collective analysis\/study. Front Cell Neurosci. 2015;9:91. doi: 10.3389\/fncel.2015.00091 .","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"712_CR63","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/jop.1987.3.211","volume":"3","author":"M Testa","year":"1987","unstructured":"Testa M, Iuliano G, Morton P, Longoni A. Topical benzyl alcohol reduces cataract surgery need: two long-term double blind studies. J Ocul Pharmacol. 1987;3(3):211\u201325.","journal-title":"J Ocul Pharmacol"},{"issue":"4","key":"712_CR64","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1248\/yakushi.129.495","volume":"129","author":"M Ahuja","year":"2009","unstructured":"Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Stability studies on aqueous and oily ophthalmic solutions of diclofenac. Yakugaku Zasshi. 2009;129(4):495\u2013502.","journal-title":"Yakugaku Zasshi"},{"key":"712_CR65","unstructured":"Grant WM, Schuman JS. Toxicology of the eye: effects on the eyes and visual system from chemicals, drugs, metals and minerals, plants, toxins, and venoms; systemic side effects from eye medications. 4th 675 edi., Springfield: Charles C Thomas Pub Ltd; 1993. p. 575."},{"issue":"1","key":"712_CR66","first-page":"51","volume":"13","author":"W Massmann","year":"1956","unstructured":"Massmann W. Toxicological investigations on dimethylformamide. Br J Ind Med. 1956;13(1):51\u20134.","journal-title":"Br J Ind Med"},{"issue":"1","key":"712_CR67","first-page":"61","volume":"9","author":"C Hanna","year":"1977","unstructured":"Hanna C, Fraunfelder FT, Meyer SM. Effects of dimethyl sulfoxide on ocular inflammation. Ann Ophthalmol. 1977;9(1):61\u20135.","journal-title":"Ann Ophthalmol"},{"issue":"5","key":"712_CR68","first-page":"646","volume":"23","author":"PL Kaufman","year":"1982","unstructured":"Kaufman PL, Erickson KA. Cytochalasin B and D dose-outflow facility response relationships in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1982;23(5):646\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"712_CR69","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1167\/iovs.02-1068","volume":"44","author":"JL Bourges","year":"2003","unstructured":"Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"712_CR70","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","volume":"17","author":"G Prosperi-Porta","year":"2016","unstructured":"Prosperi-Porta G, Kedzior S, Muirhead B, Sheardown H. Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery. Biomacromolecules. 2016;17(4):1449\u201357. doi: 10.1021\/acs.biomac.6b00054 .","journal-title":"Biomacromolecules"},{"issue":"9","key":"712_CR71","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17435390.2016.1210692","volume":"10","author":"W Wu","year":"2016","unstructured":"Wu W, Yan L, Wu Q, Li Y, Li Q, Chen S, et al. Evaluation of the toxicity of graphene oxide exposure to the eye. Nanotoxicology. 2016;10(9):1329\u201340. doi: 10.1080\/17435390.2016.1210692 .","journal-title":"Nanotoxicology"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-017-0712-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-017-0712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-017-0712-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T14:23:44Z","timestamp":1568730224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-017-0712-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1208\/s12249-017-0712-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}